PA
PDLI

Perceptive Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Perceptive Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-30,151
Closed -$232K – 202
2014
Q4 		$232K Buy
30,151
+19,968
+196% +$158K 0.02% 136
2014
Q3 		$76K Hold
10,183
– – 0.01% 124
2014
Q2 		$99K Buy
+10,183
New +$90.8K 0.01% 113

Other funds holding PDLI

First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Perceptive Advisors's PDLI Position: Q1 2015 in Review

Perceptive Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2015, closing a stake of 30,151 shares — an estimated $232K sold.

Perceptive Advisors first reported a position in PDLI in Q2 2014 and held it in 3 quarters. The position peaked at $232K in Q4 2014. 215 funds tracked by Wall St. Rank hold PDLI as of Q1 2015.

  • Perceptive Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2015 after selling out during the quarter.
  • Perceptive Advisors sold 30,151 PDL BioPharma, Inc. shares in Q1 2015, an estimated $232K.
  • Perceptive Advisors first reported a position in PDL BioPharma, Inc. in Q2 2014 and held it in 3 quarters.
  • Perceptive Advisors's PDL BioPharma, Inc. position peaked at $232K in Q4 2014.
  • 215 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2015.

Based on Perceptive Advisors's 13F filing for Q1 2015, filed 15 May 2015.